Navigation Links
Pharmasset Reports Fiscal First Quarter 2011 Financial Results
Date:2/7/2011

8 in mid-2011

-- Bristol-Myers Squibb is anticipated to initiate a combination trial of PSI-7977 and BMY-790052 during the first half of 2011

-- Pharmasset plans to submit an IND for PSI-661 in the first quarter of 2011 and to initiate a phase 1 trial in the second quarter of 2011

-- Roche expects to initiate INFORM-SVR with RG7128 and RG7227 in the first quarter of 2011

-- Roche expects to initiate a Phase 2 study with RG7128 in HCV genotype 2/3 patients in the first half of 2011

-- Roche expects to initiate a Phase 3 program with RG7128 in 2011 and file in 2013

About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys® plus Copegus® and is also in the INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage HCV candidates include PSI-7977, an unpartnered uracil nucleotide analog that has recently initiated dosing in two Phase 2b studies in patients with HCV genotypes 1, 2, or 3, and PSI-938, an unpartnered guanosine nucleotide analog which recently completed a 14-day monotherapy study and has recently initiated a 14-day combination study with PSI-7977. We also have in our pipeline an addition
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... ARBOR, Mich. , Sept. 18, 2014  A ... Research will allow the University of Michigan to establish ... The Glenn Center for Aging Research at ... evidence that drugs can slow the effects of aging ... unlock mechanisms of aging that can help develop medications ...
(Date:9/18/2014)...  Neurotrope, Inc. (OTCQB: NTRP) today announced the appointment ... the Company,s Board of Directors, effective September 12, 2014. ... the Board of seven members. Dr. Altstiel will also ... and a member of the Audit and Compensation Committees ... Scientific Advisory Board, a position he has held since ...
(Date:9/18/2014)... Sept. 18, 2014  Spring Bank Pharmaceuticals, Inc., ... the treatment of RNA viruses, today announced a ... (NIH) for animal testing of the Company,s lead ... as "Special Pathogens," against which currently there are ... Spring Bank,s proprietary Small Molecule Nucleic ...
Breaking Medicine Technology:$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2
... 31 Reportlinker.com announces that a new market ... Diagnostic Imaging Market to 2016 - ... the Key Revenue Generators ... to 2016 - Nuclear Imaging Systems and Ultrasound ...
... Reportlinker.com announces that a new ... its catalogue: Pharmaceutical ... Markets to Drive Growth but Talent ... a Challenge ...
Cached Medicine Technology:Reportlinker Adds Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the Key Revenue Generators 2Reportlinker Adds Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the Key Revenue Generators 3Reportlinker Adds Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the Key Revenue Generators 4Reportlinker Adds Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the Key Revenue Generators 5Reportlinker Adds Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the Key Revenue Generators 6Reportlinker Adds Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the Key Revenue Generators 7Reportlinker Adds Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the Key Revenue Generators 8Reportlinker Adds Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the Key Revenue Generators 9Reportlinker Adds Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the Key Revenue Generators 10Reportlinker Adds Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the Key Revenue Generators 11Reportlinker Adds Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the Key Revenue Generators 12Reportlinker Adds Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the Key Revenue Generators 13Reportlinker Adds Pharmaceutical Contract Sales Organizations (CSO) - Emerging Markets to Drive Growth but Talent Acquisition in Specialty Secondary Care Remains a Challenge 2Reportlinker Adds Pharmaceutical Contract Sales Organizations (CSO) - Emerging Markets to Drive Growth but Talent Acquisition in Specialty Secondary Care Remains a Challenge 3Reportlinker Adds Pharmaceutical Contract Sales Organizations (CSO) - Emerging Markets to Drive Growth but Talent Acquisition in Specialty Secondary Care Remains a Challenge 4Reportlinker Adds Pharmaceutical Contract Sales Organizations (CSO) - Emerging Markets to Drive Growth but Talent Acquisition in Specialty Secondary Care Remains a Challenge 5Reportlinker Adds Pharmaceutical Contract Sales Organizations (CSO) - Emerging Markets to Drive Growth but Talent Acquisition in Specialty Secondary Care Remains a Challenge 6Reportlinker Adds Pharmaceutical Contract Sales Organizations (CSO) - Emerging Markets to Drive Growth but Talent Acquisition in Specialty Secondary Care Remains a Challenge 7
(Date:9/18/2014)... Wis. (PRWEB) September 18, 2014 It is ... engage in health and wellness. Once again, Evensong Spa ... Spa Week by offering three services at a special $50 ... Spa, managed by Marcus Hotels & Resorts , is ... national event encouraging Americans to embrace health and wellness by ...
(Date:9/18/2014)... exercise is good for you. But new research from ... an added benefit for cancer patients undergoing chemotherapy. , ... found that combining exercise with chemotherapy shrunk tumors more ... professor in the School of Nursing and director of ... the senior author on the study, which appears in ...
(Date:9/18/2014)... Salt Lake City, UT (PRWEB) September 18, 2014 ... across North America will be recognizing their shared fundraising ... on Thursday, Sept. 25. , The first-ever Dance ... of more than $20 million projected to be raised ... at their community’s CMN Hospital. Donations generated through Dance ...
(Date:9/18/2014)... -- don,t worry, it,s a good thing! As scientists ... are bad. Many active enzymes and bacteria are merely ... an important part of our digestive system or can ... , an opportunistic yeast pathogen and model organism for ... personal ecosystem. However, when our immune system is stressed ...
(Date:9/18/2014)... ANGELES (September 18, 2014) The National Institutes ... funding from a four-year, $1.3 million grant to the ... in the research and development of a vaccine to ... and Methicillin-resistant Staphylococcus aureus (MRSA). , ... of the NIH awarded the grant to LA BioMed ...
Breaking Medicine News(10 mins):Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... MOUNTAIN VIEW, Calif., April 25 MAP,Pharmaceuticals, Inc. (Nasdaq: ... following upcoming investor conferences on April 30th and,May 6th, 2008:, ... Wednesday, April 30, 2008 9:10 am, Eastern Time, ... Tuesday, May 6, 2008 10:10 am, Eastern Time ...
... N.C., April 25 Managing multi-generational,diversity is emerging ... study with 23 leading companies, 80 percent deem ... yet only one-third say,their companies offer training in ... download an excerpt of,this new research, The High-Performing ...
... Malaria,Day, the American Red Cross is joining with its ... to this deadly disease., Each year, malaria, a ... mostly children in Africa. More,than 1 million people die ... the American Red Cross and its partners in the ...
... Leaders for ... World Malaria Day, World ... Bill, WASHINGTON, April 25 A volunteer nurse from,Zambia and ... to emphasize the importance of joint efforts in the,fight against malaria ...
... cancers that depend on hormones and those that ... 25th in the open-access journal PLoS Genetics. , ... which usually require treatment with surgery and anti-hormone ... hormone independent breast cancers, which are treated with ...
... THURSDAY, April 24 (HealthDay News) -- Women who play sports ... thighbone to the shinbone. Beyond the immediate pain and swelling ... type of injury may lead to another vexing health problem. ... found that young women who had surgery to repair the ...
Cached Medicine News:Health News:MAP Pharmaceuticals to Present at Upcoming Investor Conferences 2Health News:Multi-generational Diversity Top Challenge for Businesses Today: Leading Company to Share Insights June 4-6 2Health News:Uniting to Fight Malaria Around the World 2Health News:Uniting to Fight Malaria Around the World 3Health News:Government and Corporate Support Together Help Africans Battling Malaria, AIDS 2Health News:Government and Corporate Support Together Help Africans Battling Malaria, AIDS 3Health News:Women Risk Bone Loss After Knee Surgery 2Health News:Women Risk Bone Loss After Knee Surgery 3
3 mm diameter roller blade, 15 mm from angle to tip. Round handle....
2 mm wide x 3 mm long, with rounded triangular tip. Angled 45 degrees. Hexagonal handle....
Duckbill type sharp. 3 mm wide x 8 mm long curved blade. Octagonal handle....
9 mm slightly curved blade. Hexagonal handle....
Medicine Products: